BioCardia - Warrants (26/07/2022) Return on Equity

BioCardia - Warrants (26/07/2022) (BCDAW) currently reports a ROE of -271.81%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore BioCardia - Warrants (26/07/2022)'s ROE history and peer comparisons.

BioCardia - Warrants (26/07/2022)'s ROE of -271.81% is lower than the Healthcare sector average of -100.59%. That is roughly 170.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but BioCardia - Warrants (26/07/2022)'s current -271.81% should be judged against Healthcare norms (sector average: -100.59%) and against BCDAW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -271.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for BioCardia - Warrants (26/07/2022), and consider following BCDAW for alerts when major investors trade the stock.

BioCardia - Warrants (26/07/2022) is classified in the Healthcare sector. On ROE, it currently shows -271.81% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCDAW with unrelated industries.